What is the 13F Pro Quality Score for COGT?

13F Pro ranks Cogent Biosciences, Inc. (COGT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View COGT's current score at https://13fpro.ai/research/COGT (free sign-up required for the full ranking).

Which hedge funds own the most COGT stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of COGT include FMR, BlackRock,, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C). Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/COGT as soon as new 13F filings post.

Where does 13F Pro source COGT data?

All Cogent Biosciences, Inc. fundamentals and ownership data come directly from SEC EDGAR. Cogent Biosciences, Inc. files with the SEC under CIK 1622229. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is COGT in?

Cogent Biosciences, Inc. (COGT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is COGT research updated on 13F Pro?

COGT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Cogent Biosciences, Inc.(COGT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1622229 COGT stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

COGT Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Cogent Biosciences, Inc. (COGT), a Healthcare sector company. COGT is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Cogent Biosciences, Inc. reports net income of $-97.4M, free cash flow of $-87.3M. Top institutional holders of COGT by reported 13-F value include FMR, BlackRock,, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), based on the most recent SEC filings. COGT trades on the Nasdaq exchange and files with the SEC under CIK 1622229. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate COGT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cogent Biosciences, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-97.4M

Free Cash Flow

Q1 2026

$-87.3M

D/E Ratio

Q1 2026

0.37

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

—FY 2025

FY20 $7.9MFY21 —FY23 —FY25 —

Net Income

-71.0% YoY

$-328.9MFY 2025

FY20 $-74.8MFY21 $-72.3MFY23 $-192.4MFY25 $-328.9M

Operating Income

-60.2% YoY

$-333.4MFY 2025

FY20 $-82.2MFY21 $-75.6MFY23 $-208.1MFY25 $-333.4M

EPS (Diluted)

-11.3% YoY

$-2.16FY 2025

FY20 —FY21 $-1.87FY23 $-1.94FY25 $-2.16

Total Assets

+199.1% YoY

$937.6MFY 2025

FY20 $250.9MFY21 $232.1MFY23 $313.4MFY25 $937.6M

Total Debt

$222.9MFY 2025

FY20 —FY21 —FY23 —FY25 $222.9M

Op. Cash Flow

-72.1% YoY

$-264.4MFY 2025

FY20 $-35.9MFY21 $-58.8MFY23 $-153.6MFY25 $-264.4M

Metric	FY 2025	FY 2023	FY 2021	FY 2020	FY 2019	FY 2018
Revenue	—	—	—	$7.9M -65.0%	$22.5M +131.1%	$9.7M
Net Income	$-328.9M -71.0%	$-192.4M -166.2%	$-72.3M +3.4%	$-74.8M -135.0%	$-31.8M +7.8%	$-34.5M
Operating Income	$-333.4M -60.2%	$-208.1M -175.5%	$-75.6M +8.1%	$-82.2M -155.5%	$-32.2M +10.6%	$-36.0M
EPS (Diluted)	$-2.16 -11.3%	$-1.94 -3.7%	$-1.87	—	—	—
Total Assets	$937.6M +199.1%	$313.4M +35.0%	$232.1M -7.5%	$250.9M +407.7%	$49.4M -42.5%	$85.9M
Total Debt	$222.9M	—	—	—	—	—
Operating Cash Flow	$-264.4M -72.1%	$-153.6M -161.4%	$-58.8M -63.9%	$-35.9M +13.6%	$-41.5M -27.8%	$-32.5M

AI Insight: COGT Financial Trends

Cogent Biosciences remains pre-revenue with cash burn accelerating sharply — operating cash outflow hit $87M in Q1 2026, the worst on record.

• Operating cash outflow worsened from $43M in Q2 2024 to $87M in Q1 2026, a near-doubling of quarterly burn rate.

• Total debt surged from $44M in Q2 2025 to $223M in Q4 2025, reflecting significant new debt financing.

• Equity rebounded from $155M in Q2 2025 to $636M in Q4 2025, likely from a capital raise, before declining to $608M in Q1 2026.

⚠ Net loss widened to $102M in Q4 2025 and remained elevated at $97M in Q1 2026 — burn is intensifying with no revenue offset.

⚠ Equity erosion from $636M to $608M in one quarter suggests the capital raise runway is being consumed rapidly.

⚠ Debt load jumped to $223M — monitor covenant terms and refinancing risk given zero revenue generation.

AI Insight: COGT Ratio Trends

Return metrics show meaningful recovery from Q2 2025 trough, but all profitability ratios remain deeply negative for this clinical-stage biotech.

• ROE improved sharply from -189.7% in Q2 2025 to -64.1% in Q1 2026, recovering nearly to Q2 2024 levels.

• ROA recovered from a trough of -82.9% in Q4 2024 to -43.1% in Q1 2026, the least negative reading in the dataset.

• ROIC bounced from -96.2% in Q3 2025 to -49.9% in Q1 2026, though still deeply negative.

• D/E rose modestly from 0.35 in Q4 2025 to 0.37 in Q1 2026, remaining low relative to equity — typical for a cash-funded biotech.

⚠ OpMargin and NPM are absent throughout the dataset — absence of revenue generation remains the core financial risk.

⚠ ROE and ROIC deteriorated dramatically into Q2 2025 (-189.7% and -96.2%); monitor for any recurrence of that burn acceleration.

⚠ D/E crept back up to 0.37 in Q1 2026 after hitting 0.15 in Q3 2025 — watch whether leverage drifts higher as cash depletes.

Get alerted when COGT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Cogent Biosciences, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of COGT

FMR LLC
$890.0M23,122,748 sh
BlackRock, Inc.
$617.6M16,045,014 sh
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$348.1M9,043,903 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$282.3M7,333,333 sh
VANGUARD CAPITAL MANAGEMENT LLC
$265.4M6,894,959 sh
JANUS HENDERSON GROUP PLC
$229.6M5,965,125 sh
STATE STREET CORP
$218.0M5,663,543 sh
Fairmount Funds Management LLC
$211.8M5,503,418 sh
RTW INVESTMENTS, LP
$210.1M5,458,675 sh
TCG Crossover Management, LLC
$190.4M4,946,894 sh

Fund	Value	Shares
FMR LLC	$890.0M	23,122,748
BlackRock, Inc.	$617.6M	16,045,014
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	$348.1M	9,043,903
VANGUARD PORTFOLIO MANAGEMENT LLC	$282.3M	7,333,333
VANGUARD CAPITAL MANAGEMENT LLC	$265.4M	6,894,959
JANUS HENDERSON GROUP PLC	$229.6M	5,965,125
STATE STREET CORP	$218.0M	5,663,543
Fairmount Funds Management LLC	$211.8M	5,503,418
RTW INVESTMENTS, LP	$210.1M	5,458,675
TCG Crossover Management, LLC	$190.4M	4,946,894

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put COGT on your watchlist

Track score changes the day Cogent Biosciences, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is COGT a good stock to buy?

13F Pro's AI-powered analysis of Cogent Biosciences, Inc. (COGT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for COGT are available on the COGT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own COGT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling COGT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Cogent Biosciences, Inc.'s investment landscape.